Skip to content

Research on the effect of combined use of antidepressants on the treatment outcome of depression

Efficacy, safety and biological mechanism of combined use of antidepressants on depression treatment outcomes

Status
Active, not recruiting
Phases
Early Phase 1
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR2100049646
Enrollment
Unknown
Registered
2021-08-07
Start date
2021-09-01
Completion date
Unknown
Last updated
2022-04-19

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Depression

Interventions

Healthy control group:None
Depression group:Medications

Sponsors

Daizhuang Hospital of Shandong Province
Lead Sponsor

Eligibility

Sex/Gender
All
Age
15 Years to 55 Years

Inclusion criteria

Inclusion criteria: 1. Outpatient or inpatient patients aged 15 to 55 years (including 15 and 55), regardless of gender; 2. Meet the diagnostic and statistical manual of mental disorders 5th edition (DSM-5) diagnostic criteria for depressive disorders (diagnosis confirmed by the MINI stereotyped interview), either the first episode or the relapse; 3. HAMD-17 total score >=14 at screening; 4. Primary school education level or above, able to understand the content of the scale; 5. The patient himself signed the informed consent.

Exclusion criteria

Exclusion criteria: 1. Currently or in the past with DSM-5 other important diagnoses other than depressive disorders, including schizophrenia, schizoaffective disorder, bipolar disorder, neurodevelopmental disorder and neurocognitive disorder; 2. Patients with a history of alcohol and drug dependence; 3. The course of the depressive episode >= 2 years; 4. Patients with refractory depression (with 2 antidepressants with different mechanisms of action for this episode, the symptoms are relieved by a sufficient amount and a full course of treatment <50%); 5. Pregnant or lactating patients; 6. At present, there are serious physical diseases that the researchers think are not suitable to be included in this study; 7. Any other situation that the investigator considers unsuitable for inclusion.

Design outcomes

Primary

MeasureTime frame
Change of score of HAMD-17 compared with baseline assessment;

Secondary

MeasureTime frame
Change of score of QIDS-SR16 compared with baseline assessment;Functional magnetic resonance imaging;Blood and fecal metabolites;

Countries

China

Contacts

Public ContactCui Jian

Daizhuang Hospital of Shandong Province

ajian102139@126.com+86 13655379322

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 6, 2026